Related Experiment Videos
Modulation of pain perception in man by a vasopressin analogue
1Institut für Psychologie der Christian-Albrechts-Universität, Kiel, Germany.
Abstract:
The aim of the present experiment was to test whether vasopressin modulates pain perception in man. Twenty-four male volunteers participated in four sessions, each 2 weeks apart. After an adaptation session the subjects were treated intranasally with either 30 or 60 micrograms desmopressin (DDAVP) or placebo according to a cross-over double-blind design. Pain induction involved mechanical, thermal, and ischemic stimulation DDAVP had no unitary effects on pain perception in the different pain tests. The 30 micrograms dose induced sensitization to thermal stimuli. Neither treatment influenced ischemic pain perception. The mechanical pain threshold of the index finger was increased by the 60 micrograms dose only. After treatment with either dosage of DDAVP the subjects generally tolerated the pressure on their index finger for a longer time than after placebo treatment.
Insights
Desmopressin (DDAVP) shows mixed effects on pain perception. While it did not alter ischemic pain, higher doses increased mechanical pain tolerance and sensitization to thermal stimuli in male volunteers.
Area of Science:
- Neuroscience
- Pain Research
- Pharmacology
Background:
- Vasopressin, a peptide hormone, plays a role in various physiological processes.
- Its influence on human pain perception remains incompletely understood.
- Desmopressin (DDAVP), a synthetic analogue of vasopressin, is used clinically.
Purpose of the Study:
- To investigate the effects of intranasal desmopressin (DDAVP) on pain perception in healthy male volunteers.
- To determine if DDAVP modulates responses to mechanical, thermal, and ischemic pain stimuli.
- To assess dose-dependent effects of DDAVP on pain thresholds and tolerance.
Main Methods:
- Double-blind, placebo-controlled, cross-over study design.
- Twenty-four male volunteers received intranasal DDAVP (30 or 60 micrograms) or placebo.
- Pain was induced using mechanical (pressure), thermal, and ischemic stimulation.
Main Results:
- DDAVP exhibited varied effects across different pain modalities.
- A 30 microgram dose of DDAVP induced sensitization to thermal pain stimuli.
- A 60 microgram dose of DDAVP increased the mechanical pain threshold and tolerance for pressure on the index finger.
- Ischemic pain perception was not significantly influenced by DDAVP treatment.
Conclusions:
- Intranasal desmopressin (DDAVP) has differential effects on pain perception, influencing thermal and mechanical pain but not ischemic pain.
- Higher doses of DDAVP may enhance tolerance to mechanical pain stimuli.
- Further research is warranted to elucidate the precise mechanisms of vasopressin in pain modulation.